Home / Pharmaceutical / US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer

US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer

Published: Jan 2011 | No Of Pages: 31 | Published By: Assessment Group

Product Synopsis

 
Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment. 
 
Patient case highlights
 
In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose… 
 
In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with… 
 
Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer. 
 
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 
 
This report allows you to:
 
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
 
Two patient specific case scenarios that unfold throughout the report, presented to high-prescribing oncologists on ER/PR HER2/neu Negative Metastatic Breast Cancer for their clinical decisions. In a survey including 174 oncologists’ responses, for specified patient with ER/PR positive HER2/neu negative metastatic breast cancer with comorbidities, 6 in 10 oncologists would….
Executive Summary
 
Chapter 1: Introduction
Table 1. Treatment Options in Metastatic Breast Cancer
 
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
 
Chapter 3: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer
Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.1
Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.2
Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.3
Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.4
Factors Influencing Treatment Choice with ER/PR positive HER2/neu Negative Metastatic Breast Cancer
Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.5
 
Chapter 4: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer with Comorbidities
Confidence managing patient with metastatic breast cancer with multiple comorbidities
Figure 4.1
Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 4.2
Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
Figure 4.3
Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
Figure 4.4
Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities
Figure 4.5
 
Chapter 5: Summary
Appendix A: Survey Instrument
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +